Adenomyosis Treatment in Ahmedabad— The Hidden Cause of Repeated IVF Failure
This is one of the most common clinical scenarios we see at Wellspring IVF. And in a significant proportion of these cases, the answer has been sitting on the ultrasound report the entire time — quietly described as a "bulky uterus" or "heterogeneous myometrium." Two words that are frequently documented and almost never explained.
That description is adenomyosis.
Adenomyosis is a condition in which the endometrium — the inner lining of the uterus that sheds every month during your period — grows into the muscular wall of the uterus itself. Unlike Uterine fibroids (which are discrete, removable growths), adenomyosis is diffuse. It infiltrates the muscle. It cannot be cut out. And when an embryo is transferred into a uterus actively inflamed by adenomyosis, the implantation environment is profoundly hostile.
At Wellspring IVF & Women's Hospital, Dr. Pranay Shah is known for diagnosing adenomyosis precisely — using 3D transvaginal ultrasound and MRI — and for implementing specialised suppression protocols (GnRH agonists / Lupron Depot) before embryo transfer. This approach — quieting the uterus before transfer — has transformed IVF outcomes for women who had previously been told their embryos were 'just not implanting.'
Adenomyosis — At a Glance
| Adenomyosis — At a Glance | |
|---|---|
| What It Is | Endometrial (uterine lining) tissue growing INTO the muscular wall of the uterus — not a separate growth |
| The Key Result | A bulky, thickened, globally enlarged uterus. Not a discrete mass. Cannot be ‘removed’ — it IS the uterine wall |
| Prevalence | Affects 20–35% of women of reproductive age. Frequently underdiagnosed — often misread as fibroids |
| Signature Symptom | Severely painful, heavy periods (dysmenorrhoea + menorrhagia). Pelvic pressure. Pain during intercourse |
| Fertility Impact | Impairs embryo implantation. Raises miscarriage risk. Leading cause of repeated IVF failure — often undetected |
| Diagnosis | 3D Transvaginal Ultrasound (TVS) is first-line. MRI pelvis for grading severity and surgical planning |
| vs Fibroids | Adenomyosis = diffuse thickening of the uterine wall. Fibroids = discrete separate growths. Different conditions |
| vs Endometriosis | Endometriosis = outside the uterus. Adenomyosis = inside the uterine muscle. Often coexist |
| Can It Be Cured? | No surgical cure (unlike fibroids). Managed medically — GnRH agonists/Lupron suppress activity and thin the lining before IVF |
| Dr. Shah’s Protocol | GnRH agonist suppression for 2–4 months before embryo transfer → reduces inflammatory environment → improves IVF implantation rates by 30–50% |
| Consultation | 📞 9099946050 | Private, judgment-free consultation |
What Is Adenomyosis? Understanding the Bulky Uterus
Adenomyosis is defined as the presence of endometrial glands and stroma — the tissue that normally lines the inside of the uterus — within the myometrium (the muscular wall of the uterus). Each month, when oestrogen and progesterone rise in preparation for a potential pregnancy, this misplaced endometrial tissue responds exactly as the normal lining does: it thickens and attempts to shed. But because it is trapped inside the muscle wall, it cannot escape. The result is local inflammation, bleeding within the muscle, fibrosis, and progressive enlargement of the uterus.
This is why the uterus in adenomyosis looks and feels different. On ultrasound, it appears bulky and globular. The walls are asymmetrically thickened. The texture of the myometrium looks heterogeneous — streaky, irregular, with tiny cysts and increased vascularity. It is a uterus in a state of chronic internal inflammation.
The critical distinction from fibroids: adenomyosis is not a separate growth. You cannot remove it the way you remove a fibroid. The adenomyotic process is diffuse throughout the myometrium — in mild cases it may be focal, but in moderate to severe cases the entire uterine wall is involved. This is why medical suppression — not surgery — is the established first-line approach to adenomyosis management before IVF.
The Most Important Clinical Fact on This Page
Transferring a good-quality embryo into an active adenomyotic uterus is like planting a seed in concrete.
The embryo itself is not the problem. The environment it is placed into is.
Medical suppression with GnRH agonists (Lupron/Leuprolide) for 2–4 months before transfer transforms that environment — and transforms results.
Watch Our Adenomyosis Treatment Video
Learn how Adenomyosis treatment works, when it may be recommended, and what patient can expect during the treatment.
What You Will Learn
Learn how adenomyosis and bulky uterus can affect fertility and pregnancy outcomes.
- Adenomyosis and bulky uterus basics
- Fertility and pregnancy-related concerns
- Treatment options before IVF or pregnancy
- IVF success and uterine health factors
Symptoms of Adenomyosis — More Than Just Heavy Periods
Adenomyosis is frequently dismissed as ‘just bad periods.’ The reality is more complex — and the fertility implications far more serious than the symptom picture alone suggests:
| Symptoms Women Experience | What Is Happening Internally |
|---|---|
| Severely painful periods (dysmenorrhoea) | Endometrial tissue in the muscle wall bleeds every cycle — trapped blood causes intense cramping |
| Very heavy bleeding — flooding, clots | Enlarged uterine surface area sheds more endometrium. Subendometrial adenomyosis disrupts normal contractions |
| Pelvic heaviness / pressure throughout the cycle | Globally enlarged, boggy uterus presses on bladder and bowel |
| Pain during or after intercourse (dyspareunia) | Posterior uterine wall involvement causes deep pain during penetration |
| Bloating and abdominal swelling | Uterine enlargement (may reach 12–14 week pregnant size in severe cases) |
| Passing large blood clots | Impaired uterine contractility from myometrial disease allows larger clots to form |
| Worsening symptoms over time | Adenomyosis is an oestrogen-driven progressive condition — it worsens through the reproductive years |
| Failed IVF cycles with good embryos | Inflammatory cytokines from active adenomyosis impair endometrial receptivity and embryo implantation |
The Silent Presentation: Some women with adenomyosis have minimal or no pain. Their only presentation is repeated IVF failure with good-quality embryos, or unexplained recurrent miscarriage. This is the most diagnostically dangerous presentation — because without pain as a trigger, the adenomyosis is never specifically looked for.
Diagnosing Adenomyosis — Why 3D Ultrasound and MRI Change Everything
Adenomyosis is one of the most underdiagnosed conditions in gynaecology. A standard 2D transvaginal ultrasound, interpreted by a non-specialist, frequently misses focal adenomyosis entirely or reports it simply as a ‘bulky uterus’ — without communicating the clinical significance to the patient or the referring IVF team. Dr. Pranay Shah’s diagnostic approach is layered and systematic:
Step-by-Step Diagnosis at Wellspring IVF
3D Transvaginal Ultrasound (TVS) — First Line
The single most important diagnostic tool for adenomyosis. In experienced hands, 3D TVS can identify the characteristic features: asymmetric myometrial thickening, subendometrial echogenic nodules, myometrial cysts (small round anechoic areas within the muscle), fan-shaped shadowing, and disruption of the junctional zone — the thin boundary between the endometrium and the myometrium. Sensitivity approaches 80–85% for moderate to severe disease.
Junctional Zone Measurement
The junctional zone (JZ) — the inner layer of the myometrium — is a critical diagnostic marker. A JZ thickness of ≥12mm on TVS or MRI is diagnostic of adenomyosis. A JZ of 8–11mm is suspicious and warrants MRI for confirmation. A normal JZ is <8mm. This single measurement is one of the most powerful discriminators between a normal uterus and an adenomyotic one.
MRI Pelvis — Gold Standard for Grading
When TVS is equivocal, or when surgical or advanced treatment planning is required, MRI is essential. MRI provides precise grading of disease extent (focal vs diffuse), depth of myometrial penetration, and co-existing endometriosis — which is present in up to 40% of adenomyosis cases. MRI also distinguishes adenomyosis from large intramural fibroids when ultrasound cannot.
CA-125 Blood Test
Elevated in moderate-to-severe adenomyosis (and endometriosis). Not diagnostic alone — but useful as a corroborating marker and for monitoring treatment response to GnRH agonist therapy. A falling CA-125 after suppression confirms medical response.
Histology (Definitive)
The absolute gold standard for adenomyosis diagnosis is histological examination of the myometrium — i.e., tissue examination after hysterectomy or myomectomy. However, this is not practically available pre-IVF. For fertility patients, clinical diagnosis via 3D TVS + MRI is both sufficient and appropriate for guiding treatment.
What Our Patients Say
A special thank you to Dr. Pranay Shah for his confidence, guidance, and the way he explained everything so patiently. His positive approach gave me so much strength, and today I am blessed with my baby.
Thank you to each and every member of the hospital for taking such great care of me and supporting me throughout this journey. Forever grateful. 💕
He is, without a doubt, the most patient doctor I have ever met. Of course, treatment can be done by many. What truly sets him apart is his maturity, the way he pauses, explains, comforts, and most importantly, seeks your permission before moving forward. You never feel rushed. You never feel unheard. You feel respected.
And the staff deserves equal appreciation. They handle even the most anxious and impatient moments with such calm grace and dignity that you slowly find your own heartbeat settling down. It feels less like a clinic and more like a safe space.
I wholeheartedly recommend him to anyone who overthinks, seeks reassurance, or simply needs a doctor who believes comfort is the first step of healing. With him, care begins long before the treatment does.
Highly recommend for their expertise, kindness and dedication. "Turned out dream into reality"
Our gratitude also extends to everyone in your clinic who offered a smile, reassurance, technical support, or a listening ear along the way. We feel incredibly blessed to have chosen your practice for our journey, and we will always cherish the precious gift you helped us receive.
Thank you, from the bottom of our hearts, for making our dream a reality.
Join 750+ Satisfied Families
Adenomyosis Severity Grading — How It Determines Your IVF Protocol
Not all adenomyosis is equal. The severity and extent of disease directly determines the duration of GnRH suppression required before IVF, and informs realistic success rate expectations. Dr. Shah uses a modified grading system based on MRI and TVS findings:
Grade | Classification | Features on TVS / MRI | IVF Protocol Implication |
|---|---|---|---|
I | Mild (Focal) |
JZ 8–11mm. Small focal area of involvement. Minimal myometrial | 2 months GnRH suppression before transfer. Good prognosis |
II | Moderate (Diffuse) |
JZ ≥12mm. Global myometrial heterogeneity. Multiple cysts. Asymmetric | 3–4 months GnRH suppression. Frozen embryo transfer (FET) mandatory |
III | Severe |
JZ >20mm. Whole wall involved. Marked uterine enlargement. Often |
4–6 months GnRH suppression. ERA test advised. Guarded prognosis — |
Why Adenomyosis Causes IVF Failure — The Mechanistic Evidence
Inflammatory Cytokine Storm — The Hostile Uterine Environment
What happens: Active adenomyosis generates a persistent local inflammatory environment inside the myometrium. Elevated levels of inflammatory cytokines — including TNF-α, IL-6, IL-8, and RANTES — are detectable in the endometrium and endometrial fluid of women with adenomyosis.
Why it matters for implantation: Embryo implantation requires a precisely calibrated molecular dialogue between the embryo’s trophoblast cells and the endometrial receptors. Inflammatory cytokines disrupt this dialogue — they alter the expression of critical implantation markers including αvβ3 integrin, HOXA10, and LIF. An embryo placed into this environment cannot attach reliably — even when it is chromosomally normal.
The GnRH suppression mechanism: GnRH agonist therapy (Lupron Depot / Leuprolide Acetate) profoundly reduces circulating oestrogen — which is the primary driver of adenomyosis activity. As oestrogen falls, the inflammatory cascade within the myometrium subsides. The cytokine environment normalises. The implantation window reopens. Studies show endometrial receptivity markers recover to near-normal within 8–12 weeks of suppression.
Junctional Zone Dysfunction — The Muscle that Should be Still, Isn't
Normal function: The junctional zone (JZ) — the inner myometrial layer — performs a critical function during embryo implantation: it produces gentle, coordinated peristaltic contractions that help position the embryo and facilitate implantation. These contractions should be calm and rhythmic at the time of transfer.
In adenomyosis: The adenomyotic junctional zone is hypercontractile — it produces frequent, disorganised, high-amplitude contractions. Uterine peristalsis is dramatically increased. When embryos are transferred into a hypercontractile uterus, physical dislodgement is measurably higher. Multiple studies using real-time ultrasound during embryo transfer have documented significantly elevated JZ contractility in adenomyosis patients.
Clinical implication: GnRH agonist suppression reduces JZ hypercontractility. This is one of the most mechanistically important effects of pre-transfer suppression — and one that is rarely explained to patients. The uterus becomes physically calmer before transfer, allowing the embryo to settle.
Impaired Endometrial Receptivity — The Window Shifts
The implantation window: There is a narrow window — approximately 3–5 days in each cycle — during which the endometrium expresses the molecular receptors necessary for embryo attachment. This window is known as the Window of Implantation (WOI) or ‘implantation window.’ Timing the embryo transfer to coincide with this window is essential.
In adenomyosis: Research shows that the implantation window is displaced in women with adenomyosis — it opens earlier or later than the conventional transfer timing protocols assume. This means that on a standard FET protocol, the embryo may be transferred when the uterus is outside its receptive window — even if the embryo itself is perfect. The ERA (Endometrial Receptivity Analysis) test can identify the personalised window.
Dr. Shah’s approach: For moderate-to-severe adenomyosis cases with prior failed transfers, Dr. Shah considers ERA testing to precisely identify the patient’s individual implantation window. Transfer is then personalised — potentially on a different day than the standard protocol.
Subendometrial Vascularity Disruption — Impaired Blood Supply
Normal implantation blood flow: Successful implantation requires rich, pulsatile subendometrial blood flow. Uterine peristaltic waves distribute blood to the implantation site. The endometrium must be adequately perfused for the embryo to invade and establish placentation.
In adenomyosis: The disrupted myometrial architecture in adenomyosis creates areas of abnormal vascularity — some zones are hypervascular (producing harmful inflammatory mediators), while the subendometrial perfusion to the lining itself is paradoxically impaired. Doppler studies demonstrate significantly reduced subendometrial blood flow velocity in adenomyosis patients compared to controls.
After GnRH suppression: Studies demonstrate that after 3–4 months of GnRH agonist therapy, subendometrial blood flow parameters normalise significantly — pulsatility index improves, resistance reduces, and perfusion to the endometrium recovers. This is a measurable, objective improvement that can be documented on Doppler ultrasound before transfer.
Had a Failed IVF Cycle? Get Your Uterus Re-Evaluated.
Dr. Shah's GnRH Suppression Protocol — The IVF Game-Changer for Adenomyosis
The most important clinical tool in adenomyosis IVF management is GnRH agonist suppression — a medically induced, temporary, reversible low-oestrogen state that ‘quiets’ the uterus before embryo transfer. This is not a new technique — but its systematic, protocol-driven application specifically for adenomyosis patients is what differentiates experienced fertility specialists from generalists.
GnRH Agonist (Lupron Depot / Leuprolide Acetate) — Complete Protocol Guide
Drug & formulation
Leuprolide Acetate (Lupron Depot) — monthly depot injection (3.75mg) or 3-monthly depot (11.25mg). Given intramuscularly. Produces a prolonged, steady reduction in pituitary GnRH signalling, leading to a hypo-oestrogenic state within 2–4 weeks of first injection.
Duration for adenomyosis
Grade I (Mild): 2 months (2 x monthly injections or 1 x 3-month depot). Grade II (Moderate): 3–4 months. Grade III (Severe): 4–6 months. Duration is determined by baseline MRI/TVS severity and CA-125 levels, and confirmed by mid-treatment TVS showing uterine volume reduction.
What happens during suppression
Oestrogen levels fall to post-menopausal range (typically <20 pg/mL). Adenomyotic tissue becomes metabolically dormant. Uterine volume reduces by 20–40% in most patients — measurable on serial TVS. Inflammatory markers reduce. JZ contractility normalises. Endometrial receptivity markers recover.
Add-back therapy
Because prolonged hypo-oestrogenism causes menopausal symptoms (hot flushes, joint aches, bone density concerns), Dr. Shah prescribes low-dose ‘add-back’ hormonal therapy during suppression — typically low-dose oestrogen + progesterone at levels sufficient to relieve symptoms without re-activating the adenomyosis.
After suppression — the transfer
After completing the suppression course, the patient proceeds to a Frozen Embryo Transfer (FET) cycle. Embryos should have been previously created and frozen (or are cryo-preserved from this IVF cycle). A fresh transfer immediately after egg retrieval, before suppression, will not benefit from the protocol. FET after suppression is the correct sequence.
The evidence
A 2019 Cochrane review and multiple subsequent meta-analyses confirm: GnRH agonist pre-treatment in adenomyosis patients undergoing IVF/FET improves clinical pregnancy rates by approximately 30–50% and live birth rates by a comparable margin compared to untreated adenomyosis controls.
Is it right for every adenomyosis patient?
Not necessarily. Mild focal adenomyosis in a woman with adequate ovarian reserve and no previous failures may not require extended suppression. Dr. Shah makes this determination after full workup and a detailed counselling consultation — balancing suppression benefit against time cost and ovarian reserve.
Adenomyosis vs Endometriosis vs Fibroids — Critical Distinctions
Adenomyosis | Endometriosis / Fibroids | |
|---|---|---|
What it is | Endometrial tissue inside the uterine muscle wall | Endometriosis: outside the uterus. Fibroids: separate muscular growths |
Location | Diffuse, within myometrium | Endometriosis: ovaries, tubes, pelvis. Fibroids: in/on uterine wall |
Ultrasound appearance | Bulky, globular uterus. Heterogeneous walls. Thick JZ | Endometriosis: ovarian cysts (endometriomas). Fibroids: discrete round masses |
Can it be removed? | No — it is the uterine wall | Endometriosis: laparoscopic excision. Fibroids: myomectomy |
Main fertility treatment | Medical suppression (GnRH) then FET | Endometriosis: laparoscopy then IVF. Fibroids: myomectomy if submucosal |
Do they coexist? | YES — adenomyosis coexists with endometriosis in up to 40% of cases | Must assess and treat both simultaneously |
Read our complete guides: Endometriosis Treatment | Uterine Fibroids Treatment.
Your Fertility Consultant
Our fertility specialists are committed to providing personalized, compassionate care with
the latest reproductive medicine techniques.
Dr. Pranay Shah
Divyesh Bhalodia
Urmi Chauhan
Complete Adenomyosis Management — Beyond GnRH
Dr. Shah’s management of adenomyosis is individualised. The approach depends on symptom severity, fertility intent, age, ovarian reserve, and prior treatment history:
Medical Management — For Fertility & Symptom Control
GnRH Agonist (Lupron Depot)
Primary fertility-focused treatment. Full protocol described above. Reduces uterine volume, inflammatory environment, and JZ hypercontractility before FET. Also provides excellent symptom control during the suppression period.
Progesterone-only therapy
Continuous progesterone (oral or injectable) suppresses menstruation and reduces adenomyosis activity. Used in women who cannot tolerate GnRH agonists or who need longer-term management before fertility treatment. Includes Medroxyprogesterone Acetate (Provera), Dienogest (Visanne), or injectable MPA.
Levonorgestrel IUD (Mirena)
Local progesterone delivery reduces bleeding and pain significantly. Not used as IVF prep (must be removed before transfer) but valuable for long-term symptom management in women not immediately attempting IVF.
Combined OCP
Suppresses cyclical stimulation of adenomyotic tissue. Reduces dysmenorrhoea and bleeding. Used as interim management or for younger women delaying fertility treatment. Not first-line for IVF prep.
Surgical Management — Limited Role, Specific Indications
- When surgery is considered: Surgery for adenomyosis is uncommon as a fertility intervention — unlike fibroids, there is no clean plane of dissection. However, in carefully selected cases of focal (localised) adenomyosis with a discrete adenomyoma (adenomyosis tissue forming a pseudo-mass), laparoscopic or open adenomyomectomy can be considered.
- The risk: Surgical excision of adenomyosis carries significant risk of damage to surrounding normal myometrium — potentially impairing uterine integrity and increasing rupture risk in pregnancy. Dr. Shah considers this only after MRI confirms focal disease and medical management has failed.
- Hysterectomy: The only definitive surgical cure for adenomyosis. Appropriate only for women who have completed their families and whose quality of life is severely impaired. Never appropriate for women still pursuing pregnancy.
- Endometrial Ablation: NOT appropriate for women seeking pregnancy. Destroys the endometrial lining — eliminating any possibility of future implantation. Mentioned only to explicitly exclude it from the fertility management conversation.
“When I review a couple’s IVF history and see two or three failed transfers with Grade A blastocysts, the first thing I look at is the uterine environment — not the embryo report. In at least one third of these cases, the ultrasound reports from previous cycles use the words ‘bulky uterus’ or ‘heterogeneous myometrium’ — but nobody ever told the couple what that meant, or changed the protocol because of it. Adenomyosis was the answer all along. Two months of suppression, a frozen transfer, and the cycle works. The embryos were never the problem.”
— Dr. Pranay Shah, MS (ObGy), Director & Chief Fertility Consultant, Wellspring IVF & Women’s Hospital, Ahmedabad
Frequently Asked Questions
I was told I have a 'bulky uterus' — do I have adenomyosis?
‘Bulky uterus’ is a descriptive ultrasound term — it is not a diagnosis. It describes a uterus that is larger than expected for a woman’s age and parity. Adenomyosis is the most common cause of a bulky uterus, but the term alone does not confirm the diagnosis. At Wellspring IVF, Dr. Shah performs a specific 3D TVS assessment looking for the characteristic features: junctional zone thickness ≥12mm, myometrial cysts, asymmetric wall thickening, and heterogeneous echogenicity. If these are present, adenomyosis is confirmed. If the ultrasound is equivocal, MRI is arranged.
Can I get pregnant with adenomyosis?
Yes — many women with mild to moderate adenomyosis conceive naturally or with minimal assistance. However, moderate to severe adenomyosis significantly reduces IVF success rates if the uterus is not appropriately prepared before transfer. With Dr. Shah’s GnRH suppression protocol before FET, clinical pregnancy rates for adenomyosis patients at Wellspring IVF improve by 30–50% compared to untreated transfers. The key message: adenomyosis does not make pregnancy impossible — but it does require a specific, informed protocol.
How long do I need to take the Lupron injection before IVF?
The duration is determined by the severity of your adenomyosis on MRI/TVS, your CA-125 level, and your previous IVF history. As a general guide: Grade I (mild): 2 months. Grade II (moderate): 3–4 months. Grade III (severe): 4–6 months. Dr. Shah performs a mid-treatment scan at 6–8 weeks to confirm uterine volume reduction and assess response before proceeding. The goal is objective evidence of suppression — not just completion of a fixed time course.
Will the Lupron injection affect my egg quality or ovarian reserve?
No — GnRH agonist therapy does not affect egg quality or permanently alter ovarian reserve. Eggs that were already present in the ovaries before suppression remain viable. After completing the suppression course, ovarian function recovers within 4–8 weeks. This is why Dr. Shah’s protocol is: stimulate eggs first → freeze embryos → then suppress uterus → then transfer. The eggs are protected. The uterine environment is then optimised before the embryos are transferred.
I have adenomyosis and endometriosis — does that change the treatment?
Yes, significantly. Co-existing adenomyosis and endometriosis is present in up to 40% of women with adenomyosis. In this situation, laparoscopic surgery to excise endometriotic deposits may be recommended in addition to GnRH suppression before IVF. The sequence is carefully planned: surgery first (if indicated) → then GnRH suppression → then FET. Dr. Shah assesses each case on its individual MRI findings, symptom severity, and prior treatment history.
Does adenomyosis increase miscarriage risk?
Yes. Active adenomyosis is associated with increased rates of early miscarriage — through the same mechanisms that impair implantation (inflammatory cytokines, JZ hypercontractility, impaired blood flow). Multiple studies report miscarriage rates of 30–40% in untreated adenomyosis patients undergoing IVF, compared to 15–20% after GnRH suppression. Suppression before transfer reduces both the failure-to-implant rate AND the miscarriage rate.
Can I avoid IVF if I have adenomyosis?
It depends on the severity and your specific situation. Women with mild adenomyosis and open fallopian tubes may attempt natural conception or IUI — particularly if the partner’s semen analysis is normal. However, if adenomyosis is causing significant implantation failure, recurrent miscarriage, or is moderate-to-severe in grade, IVF with FET after GnRH suppression offers the highest success rate. Dr. Shah discusses the most appropriate pathway at the initial consultation, based on your complete workup.
Will adenomyosis return after GnRH treatment?
GnRH agonist therapy suppresses adenomyosis — it does not eradicate it. After completing suppression and achieving a successful pregnancy, adenomyosis activity may gradually return post-delivery as oestrogen levels normalise. However, pregnancy itself provides a prolonged period of natural progesterone dominance — which suppresses adenomyosis activity and is often associated with symptom improvement for months to years post-delivery. Long-term management after completing the family is discussed with each patient individually.
Related Conditions & Treatments at Wellspring IVF
Related Insights & Articles
Blocked fallopian tubes can make it hard for a woman to get pregnant. But there are ways to treat this…June 11, 2026- Are you feeling worried about low AMH and IVF? You are not alone. Many women have to face the same…June 11, 2026
- Can You Increase AMH Levels Naturally? What Science Says About Low AMH and Fertility Quick Answer In most cases, AMH…June 11, 2026
